AptaBio Therapeutics Inc

AptaBio Therapeutics Inc has a market capitalization of KRW 204.8 billion and a price-to-book ratio of 4.34, indicating a premium valuation relative to its book value. The company holds KRW 16.1 billion in cash and equivalents, which is a significant portion of its total assets of KRW 60.0 billion. However, it has a negative operating cash flow of KRW -15.3 billion and a free cash flow of KRW -15.96 billion, suggesting ongoing cash burn. The company's profitability metrics are negative, with a return on equity of -34.64% and a return on assets of -27.23%. These figures are below the typical thresholds for biotechnology firms, which often trade at lower or negative returns due to high R&D costs. The gross profit of KRW 1.33 billion is significantly lower than the operating loss of KRW -16.18 billion, highlighting the heavy investment in research and development. AptaBio Therapeutics Inc's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided. The company's revenue of KRW 3.70 billion is modest, and there is no indication of geographic diversification in the input data. This lack of segment and geographic detail limits the ability to assess exposure to regional risks or growth opportunities. The company's growth trajectory is uncertain, as there is no forward-looking revenue guidance provided in the input data. The current fiscal year's outlook is not quantified, and the next fiscal year's direction is also unspecified. The company's operating loss has widened significantly, and without clear signs of revenue growth or cost control, the path to profitability remains unclear. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.09, suggesting a conservative capital structure. However, the negative operating cash flow and free cash flow indicate a reliance on external financing to fund operations. The dilution risk is currently low, but the company may need to issue additional shares in the future to support its R&D activities. There are no recent events or filings provided in the input data that would indicate significant changes in the company's operations or strategy. The absence of recent transcripts or filings limits the ability to assess management's guidance or strategic direction. The company's financials suggest a focus on long-term R&D, but without recent disclosures, it is difficult to evaluate the progress of its drug development pipeline.